S3V Vascular Technologies, backed by AM Naik, has unveiled India’s first indigenous balloon-expandable Transcatheter Aortic Valve Replacement (TAVR) system. The device, designed as a minimally invasive alternative to open-heart surgery for severe aortic stenosis, enters preclinical evaluation and is expected to reach commercial launch within 12–18 months.
Introduction To The Announcement
The launch was announced on March 12, 2026, in Mysuru by S3V’s Structural Heart division. The company emphasized that the indigenous TAVR system will reduce costs significantly compared to imported valves, which currently range between ₹13–23 lakh, making advanced heart care more accessible to Indian patients.
Details Of The Device
The balloon-expandable TAVR system is designed to treat severe aortic stenosis, a condition where the aortic valve narrows and restricts blood flow. Preclinical trials will validate safety and performance, followed by clinical trials and regulatory approvals. The device aims to expand access to advanced cardiovascular procedures across India.
Strategic Importance
This launch marks a major step toward self-reliance in high-end medical technology. By developing an indigenous TAVR system, India reduces dependency on costly imports, enhances affordability, and strengthens its medtech innovation ecosystem.
Broader Implications
The indigenous TAVR system positions India as a potential hub for advanced cardiac devices. It also reflects the government’s push for “Made in India” healthcare solutions, ensuring wider access to life-saving technologies.
Key Highlights
• S3V Vascular Technologies launches India’s first indigenous balloon-expandable TAVR system
• Backed by AM Naik, Utpal Sheth, and Madhu Kela
• Preclinical evaluation underway; commercial launch expected in 12–18 months
• Imported valves cost ₹13–23 lakh; indigenous system aims to reduce costs
• Strengthens India’s medtech innovation and self-reliance in healthcare
Sources: Moneycontrol, ET HealthWorld, Business Today